Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Share News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

Share Price is delayed by 15 minutes
Get Live Data
6.15    0.05 (0.82%)
Bid:
6.10
Ask:
6.20
Spread: 0.10 (1.639%)
Market Cap: £6.35m
OPTI Live PriceLast checked at - London Stock Exchange

Intraday OptiBiotix Health Share Chart

OptiBiotix Says Research Programmes Remain On Schedule

Fri, 17th Apr 2015 07:35

LONDON (Alliance News) - OptiBiotix Health PLC said Friday that all of its research programmes remain on schedule, and that it has identified the potential to create new sugars from a wider range of microbial species than it had originally anticipated.

OptiBiotix is a life sciences business working to develop products to tackle obesity. One area it is working in is screening strains of bacteria for enzymes that produce carbohydrates consisting of a small number of sugars, with the aim of finding non-digestible sugars that can act as calorie free sweeteners.

After initial work on this project ten strains are undergoing additional testing before they are tested for their sweetness and ability to modulate the human microbiome.

"Whilst still at an early stage of development, the ability to create sugars from different species broadens the number of application areas and product and partner opportunities and mitigates development risk," said Chief Executive Officer Stephen O'Hara in a statement.

Additionally, its study for a food supplement to reduce cholesterol began in January. It is expected to complete in July.

Shares in OptiBiotix are trading up 1.9% at 40.25 pence Friday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2015 Alliance News Limited. All Rights Reserved.

Related News

EARNINGS & TRADING: Microsalt lowers sales 2026 guidance
28 May 2026

EARNINGS & TRADING: Microsalt lowers sales 2026 guidance

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately repor...

OptiBiotix reports higher revenue, improved margins
28 May 2026

OptiBiotix reports higher revenue, improved margins

(Sharecast News) - OptiBiotix Health reported higher annual revenue and improved margins for 2025 on Thursday, as the life sciences group said it was ...

WINNERS & LOSERS: Hamak jumps on gold data; MicroSalt cuts sales guide
28 May 2026

WINNERS & LOSERS: Hamak jumps on gold data; MicroSalt cuts sales guide

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.

OptiBiotix Health News

EARNINGS & TRADING: Microsalt lowers sales 2026 guidance
28 May 2026

EARNINGS & TRADING: Microsalt lowers sales 2026 guidance

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately repor...

OptiBiotix reports higher revenue, improved margins
28 May 2026

OptiBiotix reports higher revenue, improved margins

(Sharecast News) - OptiBiotix Health reported higher annual revenue and improved margins for 2025 on Thursday, as the life sciences group said it was ...

WINNERS & LOSERS: Hamak jumps on gold data; MicroSalt cuts sales guide
28 May 2026

WINNERS & LOSERS: Hamak jumps on gold data; MicroSalt cuts sales guide

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.

WINNERS & LOSERS: Auction upgrades guidance; Aquila talks break down
14 May 2026

WINNERS & LOSERS: Auction upgrades guidance; Aquila talks break down

(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Thursday.

TRADING UPDATES: OptiBiotix Health hails 2025 revenue surge
1 Apr 2026

TRADING UPDATES: OptiBiotix Health hails 2025 revenue surge

(Alliance News) - The following is a round-up of trading updates by London-listed companies, issued on Wednesday and not separately reported by Allian...

Optibiomix begins NHS trial on Wellbiome's effect on cardiac surgeries
24 Feb 2026

Optibiomix begins NHS trial on Wellbiome's effect on cardiac surgeries

(Alliance News) - Optibiotix Health PLC on Tuesday said it began a clinical trial to determine the effect of its Wellbiome fibre complex on cardiac su...

OptiBiotix launches WellBiome study with Hull NHS trust
24 Feb 2026

OptiBiotix launches WellBiome study with Hull NHS trust

(Sharecast News) - OptiBiotix Health announced the start of a clinical study with Hull University Teaching Hospitals NHS Trust on Tuesday, to assess w...

IN BRIEF: SkinBioTherapeutics board member to oversee external probe
20 Feb 2026

IN BRIEF: SkinBioTherapeutics board member to oversee external probe

SkinBioTherapeutics PLC - Newcastle Upon Tyne, England-based life sciences - Non-Executive Director Alyson Levett will oversee an independent investi...